Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis

被引:8
作者
Kim, Joon Kyung [1 ]
DePeralta, Danielle K. [2 ]
Ogami, Takuya [1 ]
Denbo, Jason W. [3 ]
Pimiento, Jose [3 ]
Hodul, Pamela J. [3 ]
Malafa, Mokenge P. [3 ]
Kim, Dae W. [3 ]
Fleming, Jason B. [3 ]
Powers, Benjamin D. [3 ,4 ]
机构
[1] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[2] Hofstra Univ, Sch Med, Northwell Hlth, New Hyde Pk, NY USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA
关键词
adenocarcinoma; CA; 19-9; antigen; outcomes; pancreatic cancer; surgery; SURVIVAL; STAGE; BIOMARKERS; CA19-9;
D O I
10.1002/jso.26103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives Current guidelines recommend neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) patients with anatomically resectable tumors but elevated CA 19-9. However, this recommendation is based on data from anatomically resectable and borderline resectable PDAC patients. Therefore, we analyzed the association of preoperative CA 19-9 with oncologic outcomes in a cohort of anatomically resectable PDAC patients. Methods A single-institution PDAC database from 2007 to 2015 included patients who underwent guideline-based staging and were anatomically resectable. Patients with bilirubin above 1.5 after decompression, nonsecretors of CA 19-9, and borderline resectable patients were excluded. Statistical analysis included frequency testing and regression modeling for recurrence and survival. Results One hundred forty-four PDAC patients were identified; 16 (11.1%) had elevated preoperative CA 19-9 >= 1000. A CA 19-9 level >= 1000 was not associated with demographic, clinical, or pathological factors. After adjustment for potential confounders, CA 19-9 levels (continuous, median, 500 U/mL, or 1000 U/mL cut-offs) were not associated with recurrence or overall survival (OS). Conclusions Although guidelines recommend CA 19-9 to determine the management of anatomically resectable PDAC patients, CA 19-9 was not associated with recurrence or OS in this cohort. Our findings do not suggest that CA 19-9 alone should determine the PDAC treatment strategy.
引用
收藏
页码:1074 / 1083
页数:10
相关论文
共 23 条
[11]   Pancreatic cancer [J].
Kamisawa, Terumi ;
Wood, Laura D. ;
Itoi, Takao ;
Takaori, Kyoichi .
LANCET, 2016, 388 (10039) :73-85
[12]   Borderline resectable pancreatic cancer: The importance of this emerging stage of disease [J].
Katz, Matthew H. G. ;
Pisters, Peter W. T. ;
Evans, Douglas B. ;
Sun, Charlotte C. ;
Lee, Jeffrey E. ;
Fleming, Jason B. ;
Vauthey, J. Nicolas ;
Abdalla, Eddie K. ;
Crane, Christopher H. ;
Wolff, Robert A. ;
Varadhachary, Gauri R. ;
Hwang, Rosa F. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 206 (05) :833-848
[13]   Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers [J].
Koay, Eugene J. ;
Amer, Ahmed M. ;
Baio, Flavio E. ;
Ondari, Alexander O. ;
Fleming, Jason B. .
CANCER LETTERS, 2016, 381 (01) :237-243
[14]   Prognostic versus predictive value of biomarkers in oncology [J].
Oldenhuis, C. N. A. M. ;
Oosting, S. F. ;
Gietema, J. A. ;
de Vries, E. G. E. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (07) :946-953
[15]  
Petrushnko Wilson, 2016, HPB (Oxford), V18, P652, DOI 10.1016/j.hpb.2016.05.004
[16]  
Poruk KE, 2013, CURR MOL MED, V13, P340
[17]  
POWERS BD, 2019, ANN SURG
[18]   Predictive and prognostic cancer biomarkers revisited [J].
Pritzker, Kenneth P. H. .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (08) :971-974
[19]   Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States [J].
Rahib, Lola ;
Smith, Benjamin D. ;
Aizenberg, Rhonda ;
Rosenzweig, Allison B. ;
Fleshman, Julie M. ;
Matrisian, Lynn M. .
CANCER RESEARCH, 2014, 74 (11) :2913-2921
[20]   Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer [J].
Rashid, Omar M. ;
Pimiento, Jose M. ;
Gamenthaler, Andrew W. ;
Nguyen, Phuong ;
Ha, Tin T. ;
Hutchinson, Tai ;
Springett, Gregory ;
Hoffe, Sarah ;
Shridhar, Ravi ;
Hodul, Pamela J. ;
Johnson, Brad L. ;
Illig, Karl ;
Armstrong, Paul A. ;
Centeno, Barbara A. ;
Fulp, William J. ;
Chen, Dung-Tsa ;
Malafa, Mokenge P. .
ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (04) :1371-1379